geopolitics

Trump’s Tariffs on Pharmaceutical Industry: What Indian Companies Should Know

Summary: The U.S. has imposed 100% tariffs on branded and patented drug imports effective October 1, 2025. Although generic drugs remain exempt from these tariffs, the announcement marks a drastic change for pharmaceutical trade which has remained unrestricted for a long time. For Indian pharmaceutical companies supplying nearly half of all generic medicines consumed in the U.S., this development requires them to reassess their market strategies, compliance frameworks, and long-term supply chain planning to navigate an increasingly complex geopolitical environment.Continue Reading Trump’s Tariffs on Pharmaceutical Industry: What Indian Companies Should Know

U.S. Tariff and Sanctions Actions Target Indian Trade: Key Considerations for Businesses

On July 30, 2025, U.S. President Donald Trump announced that the United States would impose a 25 per cent tariff on all goods imported from India. This announcement was first made via a social media post[1] and triggered widespread concern among Indian exporters and multinational stakeholders with supply chain links to India. On July 31, 2025 it was formalised by an executive order[2] which imposed varying ‘reciprocal tariffs” on a range of goods from 69 countries and European Union, including India. For countries not listed, a default rate of 10 per cent will apply. This order will be effective on August 7, 2025.Continue Reading U.S. Tariff and Sanctions Actions Target Indian Trade: Key Considerations for Businesses